These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17661697)

  • 1. Posaconazole for the management of mucosal candidiasis.
    Vazquez JA
    Future Microbiol; 2007 Jun; 2(3):245-56. PubMed ID: 17661697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.
    Vazquez JA
    Ther Clin Risk Manag; 2007 Aug; 3(4):533-42. PubMed ID: 18472974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients.
    Vazquez JA
    HIV Clin Trials; 2000; 1(1):47-59. PubMed ID: 11590489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
    Vazquez JA; Skiest DJ; Nieto L; Northland R; Sanne I; Gogate J; Greaves W; Isaacs R
    Clin Infect Dis; 2006 Apr; 42(8):1179-86. PubMed ID: 16575739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.
    Skiest DJ; Vazquez JA; Anstead GM; Graybill JR; Reynes J; Ward D; Hare R; Boparai N; Isaacs R
    Clin Infect Dis; 2007 Feb; 44(4):607-14. PubMed ID: 17243069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection.
    Vazquez JA
    Pharmacotherapy; 1999 Jan; 19(1):76-87. PubMed ID: 9917080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.
    Vazquez JA
    HIV AIDS (Auckl); 2010; 2():89-101. PubMed ID: 22096388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posaconazole: a next-generation triazole antifungal.
    Farowski F; Vehreschild JJ; Cornely OA
    Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
    Goldman M; Cloud GA; Wade KD; Reboli AC; Fichtenbaum CJ; Hafner R; Sobel JD; Powderly WG; Patterson TF; Wheat LJ; Stein DK; Dismukes WE; Filler SG; ;
    Clin Infect Dis; 2005 Nov; 41(10):1473-80. PubMed ID: 16231260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.
    Vazquez JA; Skiest DJ; Tissot-Dupont H; Lennox JL; Boparai N; Isaacs R
    HIV Clin Trials; 2007; 8(2):86-97. PubMed ID: 17507324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment.
    Powderly WG; Mayer KH; Perfect JR
    AIDS Res Hum Retroviruses; 1999 Nov; 15(16):1405-12. PubMed ID: 10555102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of the management of oral candidiasis associated with HIV/AIDS.
    Albougy HA; Naidoo S
    SADJ; 2002 Dec; 57(11):457-66. PubMed ID: 12674866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
    Nagappan V; Deresinski S
    Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of oropharyngeal candidiasis in HIV-positive patients.
    Greenspan D
    J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S51-5. PubMed ID: 7915732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole: clinical pharmacology and potential for management of fungal infections.
    Groll AH; Walsh TJ
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
    Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
    Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic tools for oral candidiasis: Current and new antifungal drugs.
    Quindós G; Gil-Alonso S; Marcos-Arias C; Sevillano E; Mateo E; Jauregizar N; Eraso E
    Med Oral Patol Oral Cir Bucal; 2019 Mar; 24(2):e172-e180. PubMed ID: 30818309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole: an oral triazole with an extended spectrum of activity.
    Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
    Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posaconazole.
    Bhattacharya M; Rajeshwari K; Dhingra B
    J Postgrad Med; 2010; 56(2):163-7. PubMed ID: 20622401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.